Is SPRUCE BIOSCIENCES, INC. (SPRB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.6% / 30% | 64.8% / 30% | 0.0% / 30% | 69.68% / 5% | ✗ NOT HALAL |
| DJIM | 4.6% / 33% | 64.8% / 33% | 0.0% / 33% | 69.68% / 5% | ✗ NOT HALAL |
| MSCI | 6.1% / 33% | 85.7% / 33% | 0.0% / 33% | 69.68% / 5% | ✗ NOT HALAL |
| S&P | 4.6% / 33% | 64.8% / 33% | 0.0% / 33% | 69.68% / 5% | ✗ NOT HALAL |
| FTSE | 6.1% / 33% | 85.7% / 33% | 0.0% / 50% | 69.68% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -109.2% | |
| Return on Assets (ROA) | -36.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $736,000 |
| Debt-to-Equity | 1.7 |
| Current Ratio | 5.2 |
| Total Assets | $53M |
Price & Trading
| Last Close | $69.11 |
| 50-Day MA | $67.23 |
| 200-Day MA | $149.27 |
| Avg Volume | 38K |
| Beta | 3.8 |
|
52-Week Range
$7.00
| |
About SPRUCE BIOSCIENCES, INC. (SPRB)
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SPRUCE BIOSCIENCES, INC. (SPRB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SPRUCE BIOSCIENCES, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SPRUCE BIOSCIENCES, INC.'s debt ratio?
SPRUCE BIOSCIENCES, INC.'s debt ratio is 4.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.1%.
What are SPRUCE BIOSCIENCES, INC.'s key financial metrics?
SPRUCE BIOSCIENCES, INC. has a market capitalization of $86M. Return on equity stands at -109.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.